New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Special RNA shown to suppress the formation of breast cancer cells

Special RNA shown to suppress the formation of breast cancer cells

JANUARY 16, 2024by Sebastian Hollstein,Friedrich Schiller University of JenaCredit:Cell Reports(2024). DOI: 10.1016/j.celrep.2023.113644Breast cancer is the most common cancer in wom
Oncology March 25,2024
Special RNA shown to suppress the formation of breast cancer cells

Special RNA shown to suppress the formation of breast cancer cells

JANUARY 16, 2024by Sebastian Hollstein,Friedrich Schiller University of JenaCredit:Cell Reports(2024). DOI: 10.1016/j.celrep.2023.113644Breast cancer is the most common cancer in wom
Oncology March 25,2024
A new treatment reduces inflammation in multiple sclerosis mice models

A new treatment reduces inflammation in multiple sclerosis mice models

by Autonomous University of BarcelonaMaR1 reduces pro-inflammatory cytokines in the spinal cord of EAE mice. Plot showing the fold change in cytokine protein levels of different cytokines in the
Neurology March 25,2024
A new treatment reduces inflammation in multiple sclerosis mice models

A new treatment reduces inflammation in multiple sclerosis mice models

by Autonomous University of BarcelonaMaR1 reduces pro-inflammatory cytokines in the spinal cord of EAE mice. Plot showing the fold change in cytokine protein levels of different cytokines in the
Neurology March 25,2024
Immune system's moonlighters point the way to a new therapeutic target

Immune system's moonlighters point the way to a new therapeutic target

FEBRUARY 20, 2024byCold Spring Harbor LaboratoryGraphical abstract. Credit:Molecular Cell(2024). DOI: 10.1016/j.molcel.2024.01.007Our immune system is remarkably powerful. It quickly
Immunology & Rheumatology March 25,2024
Immune system's moonlighters point the way to a new therapeutic target

Immune system's moonlighters point the way to a new therapeutic target

FEBRUARY 20, 2024byCold Spring Harbor LaboratoryGraphical abstract. Credit:Molecular Cell(2024). DOI: 10.1016/j.molcel.2024.01.007Our immune system is remarkably powerful. It quickly
Immunology & Rheumatology March 25,2024
A new immunologic and endocrine syndrome

A new immunologic and endocrine syndrome

by University of MontrealThese mice are twin, except that the left mouse is normal whereas the Armc5 gene has been invalidated by genetic knockout in the right mouse. The mutated mouse is smaller
Breakthroughs March 25,2024
A new immunologic and endocrine syndrome

A new immunologic and endocrine syndrome

by University of MontrealThese mice are twin, except that the left mouse is normal whereas the Armc5 gene has been invalidated by genetic knockout in the right mouse. The mutated mouse is smaller
Breakthroughs March 25,2024
Baseline findings among hospitalized mucormycosis patients: A multicentric ambispective cohort study in India

Baseline findings among hospitalized mucormycosis patients: A multicentric ambispective cohort study in India

FEBRUARY 6, 2024by Tsinghua University PressDirected acyclic graph demonstrating the relationship between potential risk factors of mortality due to mucormycosis. Credit: Dr. Rizwan Suliankatchi Abdul
Breakthroughs March 25,2024
Baseline findings among hospitalized mucormycosis patients: A multicentric ambispective cohort study in India

Baseline findings among hospitalized mucormycosis patients: A multicentric ambispective cohort study in India

FEBRUARY 6, 2024by Tsinghua University PressDirected acyclic graph demonstrating the relationship between potential risk factors of mortality due to mucormycosis. Credit: Dr. Rizwan Suliankatchi Abdul
Breakthroughs March 25,2024
Combination drug activates calcium channels to trigger deadly influx of calcium ions inside tumor cells

Combination drug activates calcium channels to trigger deadly influx of calcium ions inside tumor cells

JANUARY 29, 2024byWileyCredit:Angewandte Chemie International Edition(2024). DOI: 10.1002/anie.202317578Calcium ions are essential for cells, but can be toxic in higher concentration
Oncology March 25,2024
Combination drug activates calcium channels to trigger deadly influx of calcium ions inside tumor cells

Combination drug activates calcium channels to trigger deadly influx of calcium ions inside tumor cells

JANUARY 29, 2024byWileyCredit:Angewandte Chemie International Edition(2024). DOI: 10.1002/anie.202317578Calcium ions are essential for cells, but can be toxic in higher concentration
Oncology March 25,2024
A new vaccine that alters senescent cells in a way that pushes the immune system into removing them

A new vaccine that alters senescent cells in a way that pushes the immune system into removing them

by Bob Yirka , Medical XpressFig. 1: GPNMB is a potential candidate of seno-antigen. Credit: DOI: 10.1038/s43587-021-00151-2A team of researchers affiliated with a large number of institutions in Japa
Geriatrics March 25,2024
A new vaccine that alters senescent cells in a way that pushes the immune system into removing them

A new vaccine that alters senescent cells in a way that pushes the immune system into removing them

by Bob Yirka , Medical XpressFig. 1: GPNMB is a potential candidate of seno-antigen. Credit: DOI: 10.1038/s43587-021-00151-2A team of researchers affiliated with a large number of institutions in Japa
Geriatrics March 25,2024
How one inflammatory disorder exacerbates another

How one inflammatory disorder exacerbates another

by Katherine Unger Baillie,University of PennsylvaniaInflammation in the gums can increase susceptibility to other forms of inflammation, such as arthritis, through changes to immune cell precur
Immunology & Rheumatology March 25,2024
How one inflammatory disorder exacerbates another

How one inflammatory disorder exacerbates another

by Katherine Unger Baillie,University of PennsylvaniaInflammation in the gums can increase susceptibility to other forms of inflammation, such as arthritis, through changes to immune cell precur
Immunology & Rheumatology March 25,2024
A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy

A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainA peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint
Oncology March 25,2024
A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy

A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainA peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint
Oncology March 25,2024
Development of a novel bispecific antibody therapy to overcome myeloma heterogeneity

Development of a novel bispecific antibody therapy to overcome myeloma heterogeneity

by Ehime UniversityMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Multiple myeloma is still an incurable hematological ma
Oncology March 25,2024
Development of a novel bispecific antibody therapy to overcome myeloma heterogeneity

Development of a novel bispecific antibody therapy to overcome myeloma heterogeneity

by Ehime UniversityMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Multiple myeloma is still an incurable hematological ma
Oncology March 25,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com